Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Efficacy and Safety Study of Dutasteride Combined With Tolterodine ER or Placebo to Treat Lower Urinary Tract Symptoms (LUTS)

This study is ongoing, but not recruiting participants.
Information provided by (Responsible Party):
Paul F. Siami, MD, Siami, Paul F., M.D. Identifier:
First received: June 12, 2009
Last updated: October 17, 2013
Last verified: October 2013

This is an investigator-initiated study of safety, efficacy and tolerability of dutasteride given for 18 months, including a 1-year double-blind randomized co-administration with either tolterodine ER or placebo in men suffering from lower urinary tract symptoms (LUTS) including urgency and frequency, with or without urgency urinary incontinence (i.e., overactive bladder (OAB) symptoms).

Condition Intervention Phase
Drug: dutasteride 0.5 mg, used with tolterodine ER 4mg or placebo
Drug: dutasteride
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: A Randomized, Double-blind, Placebo-controlled, Study of Safety and Efficacy of Dutasteride in Combination With Tolterodine ER or Placebo in Men With Lower Urinary Tract Symptoms (LUTS) Including Urgency and Frequency

Resource links provided by NLM:

Further study details as provided by Siami, Paul F., M.D.:

Primary Outcome Measures:
  • To evaluate the safety of dutasteride 0.5 mg in combination with either tolterodine ER 4mg or placebo for the treatment of men with symptoms of LUTS. [ Time Frame: 19 months ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • To evaluatethe risk/incidence of acute urinary retention (AUR) in men taking dutasteride 0.5 mg in combination with either tolterodine ER 4mg or placebo for the treatment of men with LUTS including OAB symptoms. [ Time Frame: 19 Months ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 60
Study Start Date: July 2009
Estimated Study Completion Date: September 2014
Estimated Primary Completion Date: September 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: dutasteride 0.5 mg
open-label dutasteride 0.5 mg once daily for 6 months
Drug: dutasteride
open-label dutasteride 0.5 mg once daily for 6 months
Experimental: dutasteride 0.5 mg, tolterodine ER 4 mg, placebo
dutasteride 0.5 mg in combination with either tolterodine ER 4mg or placebo
Drug: dutasteride 0.5 mg, used with tolterodine ER 4mg or placebo

dutasteride 0.5 mg orally once daily for six months, followed by randomization in a 1:1 ratio into two parallel groups of

  1. dutasteride 0.5 mg once daily with tolterodine ER 4 mg orally daily for one year or
  2. dutasteride 0.5 mg once daily with tolterodine ER placebo orally daily for one year

Detailed Description:

Men who are treated with an alpha blocker (AB) or 5-alpha reductase inhibitor (5-ARI) for benign prostatic enlargement (BPE) and lower urinary tract symptoms (LUTS) often have symptoms including urinary frequency and urgency. ABs and 5-ARIs may improve the obstructive voiding symptoms but not necessarily the storage symptoms.

This study will evaluate the safety and efficacy of dutasteride 0.5 mg once daily for 6 months in an open label fashion. Those patients who continue to report storage urinary symptoms, will be randomized to receive dutasteride 0.5 mg once daily for an additional one year together with double-blind tolterodine ER 4 mg or matched tolterodine ER placebo once daily.


Ages Eligible for Study:   50 Years and older
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   No

Inclusion Criteria:

This subject population will consist of males ≥ 50 years of age who have lower urinary tract symptoms (LUTS) due to benign prostatic enlargement (BPE) for a minimum of 3 months

Inclusion criteria at screening:

  1. Subjects who understand and speak English and are able to comply with the protocol, complete the diaries, and other study tools
  2. Subject has provided written informed consent and HIPAA authorization
  3. Ambulatory male subjects ≥ 50 years of age
  4. Able to use the toilet without difficulty
  5. History of LUTS due to BPE, as diagnosed by history as well as DRE, for ≥ 3 months suitable for medical therapy with 5-ARI in combination with antimuscarinic drugs
  6. Prostate volume (PV) ≥ 30 cc as measured by TRUS
  7. IPSS ≥12
  8. Post Void Residual Volume < 150 mL at baseline
  9. Uroflowmetry-Qmax > 5 mL/sec and ≤ 15 mL/sec
  10. PSA ≥ 1.5 ng/ml and in normal age-adjusted range. For those subjects with an elevated age- adjusted PSA, it is the responsibility of the investigator to take standard of care measures to assure reasonable absence of prostate cancer
  11. Have an average of ≥ 8 micuturitions per 24 hrs
  12. Have an average of 2 episodes of urgency per 24 hrs (defined as those with the Urinary Sensation Scale rating of 3 or more)

Exclusion Criteria:

  1. Concurrent use of 5-ARI therapy within the past 3 months
  2. Concurrent use of alpha blockers within the past 2 weeks
  3. Concurrent use of antimuscarinics within the past 4 weeks
  4. Concurrent use of PDE-5 inhibitors on a daily basis
  5. Evidence of chronic inflammation such as interstitial cystitis and bladder stones.
  6. Evidence of untreated urethral stricture disease
  7. Uncontrolled narrow angle glaucoma
  8. Increased PVR defined as PVR > 150 mL
  9. Uroflowmetry-Qmax ≤ 5 mL/sec
  10. Acute urinary tract infection (UTI). These subjects may be treated and re-screened
  11. Acute urinary retention (AUR) requiring catheter within the last 3 months
  12. Previous or planned transurethral resection of the prostate (TURP)
  13. Minimally invasive surgery (MIS) such as transurethral microwave treatment (TUMT), transurethral needle ablation (TUNA), laser, or other minimally invasive procedures within 12 months. Those patients who in the opinion of the investigator did not respond adequately to MIS and fulfill the inclusion criteria are eligible to participate
  14. A known diagnosis of prostate cancer.
  15. A known diagnosis of bladder cancer within 5 years of screening. Those patients with history of non-muscle invasive bladder cancer who have not had a recurrence in the past 5 years are eligible to screen for this study and must maintain continued adequate bladder cancer screening at the discretion of the Investigator
  16. Renal or hepatic impairment defined as 2.5 x upper limit of normal. Some isolated abnormalities would be left at the discretion of the investigator with always keeping in mind to not pose a hazard to the patient.
  17. PSA > 10 ng/mL (if the PSA is greater than 4 ng/mL and less than or equal to 10 ng/mL, subjects may be included at the discretion of the Investigator if the PSA has been stable and the patient has had a prostate biopsy showing no evidence of prostate cancer)
  18. Known or suspected hypersensitivity to dutasteride or tolterodine ER .
  19. Participation in a clinical trial involving an investigational drug, within 30 days prior to enrollment.
  20. History of diagnosed gastrointestinal obstruction disease.
  21. Myocardial infarction within the past 8 weeks.
  22. Known or suspected drug and/or alcohol abuse.
  23. Any clinical condition, which, in the opinion of the Investigator, would not allow safe completion of the study.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00939120

United States, Indiana
Deaconess Clinic Gateway Health Center
Newburgh, Indiana, United States, 47630
Sponsors and Collaborators
Siami, Paul F., M.D.
Principal Investigator: Paul F Siami, MD Deaconess Clinic Research Institute
  More Information

No publications provided

Responsible Party: Paul F. Siami, MD, Medical Director, Deaconess Clinic Research Institute, Siami, Paul F., M.D. Identifier: NCT00939120     History of Changes
Other Study ID Numbers: 110983
Study First Received: June 12, 2009
Last Updated: October 17, 2013
Health Authority: United States: Food and Drug Administration

Keywords provided by Siami, Paul F., M.D.:
tolterodine ER

Additional relevant MeSH terms:
Lower Urinary Tract Symptoms
Signs and Symptoms
Urological Manifestations
5-alpha Reductase Inhibitors
Adrenergic Agents
Adrenergic Agonists
Adrenergic alpha-Agonists
Anti-Obesity Agents
Appetite Depressants
Autonomic Agents
Cardiovascular Agents
Central Nervous System Agents
Cholinergic Agents
Cholinergic Antagonists
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Muscarinic Antagonists
Nasal Decongestants
Neurotransmitter Agents
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Respiratory System Agents
Therapeutic Uses
Urological Agents
Vasoconstrictor Agents processed this record on November 20, 2014